HER-2 positive + HER-2 overexpression

P2, N=33, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=185 --> 33 | Trial completion date: Feb 2026 --> Dec 2024 | Recruiting --> Terminated; Abandon of the partner, ROCHE

Temporal analysis showed conversion rates of 50.0% for synchronous metastases, 30.8% within 12 months, and 63.6% beyond 12 months. We identified a high prevalence of HER2-low and HER2-ultralow subtypes, suggesting potential eligibility for ADC therapies.

This study identifies a significant association between HER2 overexpression and lymph node metastasis in gastric cancer, suggesting HER2 expression is associated with more advanced lymph node involvement in this cohort; no significant association with overall survival was observed (log-rank p=0.58), though its impact on survival remains inconclusive.

In summary, this study highlights the critical role of CAND1 in regulating HER2 ubiquitination and suggests a potential therapeutic strategy for patients with HER2-positive breast cancer.

CELF1 promotes aerobic glycolysis and aggressive behavior in ER-positive breast cancer, at least partly by regulating GLUT1. These findings reveal RBP-driven metabolic reprogramming in luminal A disease and nominate the CELF1-GLUT1 axis as a potential therapeutic vulnerability.

She received carboplatin/paclitaxel plus avelumab, followed by pegylated liposomal doxorubicin and weekly paclitaxel. This case illustrates that T-DXd can induce deep and durable remission in HER2-positive, dMMR metastatic serous endometrial cancer after multiple lines of therapy. It adds real-world evidence supporting further investigation of HER2-directed antibody-drug conjugates in gynaecologic malignancies, and underscores the need for confirmatory trials and refined biomarker-driven patient selection.

P2, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026

The patient subsequently received trastuzumab combined with low-dose nab-paclitaxel, achieving a partial response according to RECIST 1.1 criteria. At the most recent follow-up, the patient remains in stable condition. This case highlights the efficacy and safety of HER2-targeted combination therapy in elderly SDC patients, offering valuable insights into biomarker-driven personalized treatment strategies for this population.

HER2 expression is closely associated with meningioma pathogenesis and grade. This highlights HER2 as a potential biomarker and therapeutic target, warranting further clinical trials to explore HER2-targeted therapies, such as trastuzumab, for aggressive and non-resectable meningiomas.

This study provides multi-layered evidence for the association between members of the cathepsin family (particularly CTSE and CTSO) and breast cancer subtypes through MR analysis, bioinformatics validation, and cellular experiments. The findings highlight the potential of these markers as subtype-specific biomarkers for precision diagnosis, treatment, and prognosis evaluation in breast cancer. These results deepen our understanding of the biological mechanisms underlying breast cancer and offer both experimental and theoretical support for the development of novel therapeutic strategies targeting the cathepsin family.

P1/2, N=52, Completed, Jazz Pharmaceuticals | Active, not recruiting --> Completed

Statistically significant differences in FAPI uptake and TBR were found between tumors with HER2 overexpression and those with HER2-zero expression (p = 0.015). The study demonstrates that 68Ga-FAPI PET/CT may enhance diagnostic accuracy in aggressive BC phenotypes, particularly HER2-overexpressing tumors, and could serve as a valuable complementary imaging modality for staging and treatment planning.